"THE NEW HUNT FOR KILLER VIRUS-HEPATITIS-B" (ELIMINATION OF VIRAL HEPATITIS, AN INFECTIOUS DISEASE PHYSICIAN'S PERSPECTIVE)
Keywords:
Bilurubin, Cirrhosis, hepatocellular Carcinoma (HCC), HBsAg, Colo-Rectal Liver Metastases, Chronic hepatitis B (CHB), SeroprevalenceAbstract
Jaundice is a disease that your friends diagnose. Know safety. No infection. The liver is the largest internal organ in the body. Here, there and everywhere the Hepatitis B Virus (HBV) is present.
It is present at high levels in many different body fluids.Hepatitis has been a major plague of mankind. The clinical signs of HBV vary widely. Most cases are asymptomatic. However, sometimes fever, loss of appitite, abdominal discomfort, nausea, fatigue and other symptoms gradually appear.
Hepatitis B can cause mild illness lasting a few weeks, or it can lead to a serious, lifelong illness. The virus infects hepatic cells and causes liver tissue degeneration and release of liver associated enzymes (transaminases) into blood stream.This is followed by jaundice, accumulation of bilurubin (A black down product of hemoglobin) in skin and other tissues with resulting yellow appearance
References
I. Leu, Korea Centers for Disease Control & Prevention. Korea National Health and Nutrition Examination Survey (KNHANES) 2016 [Internet]. Cheongju (KR): KCDC, 2016
II. Cho EJ, Kim SE, Suk KT, et al. Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol 2017;23:205-211.
III. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of the worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-1555
IV. Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection 2016; 44: 575-582
V. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165
VI. Meireles C, Marinho RT, VanDamme P, Three decades of hepatitis B control with vaccination.World.Heptol 2015;7:2127-32
VII. WHO,Immunization coverage.2016.Available at htpp//www whoint/immunization/monitoring.Surveilance/routine/coverage.Index 4 html accessed April 2017.
VIII. Glynn SA, Kleiman SH, Wright DJ, Busch MP,2002.International application of the incidence rate/window period model transfusion 42(8):966-972
IX. Liu GC,Liu GY et al.Bayesian analysis on the prevalence of HBV infection among Chinese volunteers blood donor PLoS one 2013 8e/79203
X. Qian HG,Zhang J,LengJIT,et al.Association of hepatitis B virus infection and cirrhosis with liver metastasis in colorectal cancer.Zhonghua Wei Chang Wai Ke Za Zhi 2010; 13:202-4
XI. Poh Z, Goh BB, Chang PE, Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance a 10-year follow up of 673 patients.Eur.J.Gastroenterol Hepatol 2015,27:638-43
XII. Wiktor SZ, Hutin YJ , The global burden of viral hepatitis; better estimates to guide hepatitis elimination efforts.Lancet,2016 :388-:1030
XIII. VijayadevaV,spreading,Moorman AC,et al.Hepatitis B Virus infection testing and prevalence among Asian and Pacific islanders. Am.J.Manag.care 2014,20e:98e104
XIV. Yue X, Black CL, O'Halloran A, Lu PJ, Willium WW, Nelson NP.Hepatitis A and Hepatitis B vaccination coverage among adults with chronic liver disease.Vaccine,2018;36:1183-9.
XV. W. Demsiss, A. Seid, T. Fiseha, and I. Chemin, “Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia,” PLoS ONE, vol. 13, no. 5, p. e0196539, 2018.
XVI. Gill US, Peppa D, Micco L, et al. Interferon-alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in vivo. PLoS Pathog 2016; 12: e1005788.
XVII. CDC. Hepatitis B. Available online: https://www.cdc.gov/hepatitis/hbv/bfaq.htm#overview (accessed on 1 January 2019.
XVIII. World Health Organization. Hepatitis B. Available online: www.who.int/news-room/fact-sheets/detail/
hepatitis-b (accessed on 1 January 2019
XIX. Frodsham, A. J. Host genetics and the outcome of hepatitis B viral infection. Transplant immunology 14, 183–186,. 2005
XX. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747–753,
XXI. Barbara Mühlemann; et al. 2018. "Ancient hepatitis B viruses from the Bronze Age to the Medieval period". Nature. 557(7705): 418-423
XXII. Ben Guarino (9 May 2018). "New strains of hepatitis B virus discovered in ancient human remains". The Washington Post. 2018.
XXIII. Ross, Zoe Patterson; Klunk, Jennifer; Fornaciari, Gino; Giuffra, Valentina; Duchêne, Sebastian; Duggan, Ana T.; Poinar, Debi; Douglas, Mark W.; Eden, John-Sebastian 2018. "The paradox of HBV evolution as revealed from a 16th-century mummy". PLOS Pathogens. 14 (1): e1006750.
XXIV. Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A 2013. "Dating the origin and dispersal of hepatitis B virus infection in humans and primates". Hepatology. 57 (3)
XXV. Rasche A, Souza BF, Drexler JF.2016. "Bat hepadnaviruses and the origins of primate hepatitis B viruses". Current Opinion in Virology. 16: 86–94.
XXVI. Bouckaert R, Simons BC, Krarup H, Friesen TM, Osiowy C 2017. "Tracing hepatitis B virus (HBV) genotype B5 (formerly B6) evolutionary history in the circumpolar Arctic through phylogeographic modeling". PeerJ. 5: e3757.
XXVII. Ben Guarino 2018. "New strains of hepatitis B virus discovered in ancient human remains". The Washington Post. Retrieved 9 January 2018.
XXVIII. John B Carter and vnetia A Saunders,Virology principles and applications,2014,pp224.
XXIX. Richard V.Goering,Haxel M,Dockrell et al.MimsMedical microbiology 5 th Ed,Elsavier,2013
XXX. KennethJ.Ryan,C.George Ray,NafeesAhmed,W.Lawrence Drew,James,Sherris Medical microbiology 5th Ed,.Plorde.Mc Graw hill Medical,2010.
XXXI. Centers for disease control and prevention (CDC) updated CDC recommendations for the management of hepatitis B virus infected health-care providers and students.MMWR.Recommn.Rep.2012;61:1-12
XXXII. Timothy M,Block,Stephen locarnini et al.Use of current and new end points in the evaluation of experimental Hepatitis B therap[eutics.2017,Clinical infectious disease.
XXXIII. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatol 2001;34:1225-41.
XXXIV. Boyd A, Duchesne L, Lacombe K, Research gaps in viral hepatitis.J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25054.
XXXV. FattovichG,Bortolotti F,Donato F, Natural history chronic hepatitis B,Special emphesis on disease progression and prognostic factors.J.Hepatol 2008;48:335-352
XXXVI. Sartorius K, Sartorius B, Aldous C, Govender PS, Madiba TE. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 2015;39 (3):284–290.
XXXVII. Spradling PR,Rupp L,et al.Chronic hepatitis cohort study investigators.HBV and BCV infection among 1.2 million persons with access to care.Factors associated with testing and infection prevalence.Cli.Inf.Dis 2012;55:1047-55
XXXVIII. Singal AG,Tiro J,et al.J.hepatocellular carcinoma surveillance among patients with cirrhosis in a population based integrated health care delivery system.J Clin.Gastroenterol 2017;51:650-5
XXXIX. Jonas M, M,Reddy RK,De medicine M et al. Hepatitis B in a large municipal obstetrical population.Charecterization perinatal transmission.Amm.J. Gastroenterol.85;277:280.1990
XL. Mamun Al-Mahtab,SM Fazle Akbar,Salimur Rahman,Comprehensive text book of hepatitis B-Japee brothers ,Medical publishers (p) Ltd,2011.
XLI. Jereny Farrar,Peter J.Hotez,et al.Manson’s tropical diseases 23 rd edn,Elsavier,saunders,2014,Prited in China.
XLII. Surindra Kumar,Essentials of Microbiology Health sciences publisher,Jaypee brothers Medical Publisher,2016,pp 470,.
XLIII. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013;381:468-475
XLIV. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak
XLV. F, et al. Sustained HBeAg and HBsAg loss after long-term fol- low-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467.
XLVI. Hie-Won Hann, Advances in the Management of Hepatitis B Virus Infection, Gastroenterol Hepatol (N Y). 2014 Jun; 10(6): 384–386
XLVII. .Richard.V.Goering,Hazel M,Dockrell,Mark Zuckerman et al. Mims’Medical microbiology 5 ED,Int.ED,Elsavier,2013.
XLVIII. Caterina Sagnelli, Mariantonietta Pisaturo, Federica Calò, Salvatore Martini, Evangelista Sagnelli, Nicola Coppola, Reactivation of hepatitis B virus infection in patients with hemolymphoproliferative diseases, and its prevention World J Gastroenterol 2019 July 14; 25(26): 3299-3312
XLIX. Y.Kim, The national academy report on the elimination of viral hepatitis,An infectious disease,Physician perspective,Clinical infectious disease (CID),2017 :65,pp 7092.
L. . Sandhya Kamath,Sidharth.N.Shah et al. API.Text book of Medicine,11 ED,Vol-2 pp1803,2019.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.
